Description of the medicine: Pamidronate sodium (Pamidronate disodium)
Sodium Pamidronate (Pamidronate disodium).
Disodium salt of (3-amino-1-hydroxypropylidene) -diphosphonic acid.
Synonym: Arredia, Aredia.
By chemical structure and mechanism of action is close to alendronate sodium.
It inhibits the resorption of bone tissue.
T S is 27-28 h; Not exposed to biotransfomation, excreted by the kidneys.
Assign primarily to osteoporosis (osteolysis) in patients with malignant tumors with bone metastases, as well as with "steroid" osteoporosis and Paget's disease.
It is noted that with the use of the drug pain in the bones is reduced and signs of repair in the foci of osteolysis are observed.
Assign in the form of a slow infusion (can not be injected). Lyophilized powder is first diluted in water for injection (0.015 g dissolved in 5 ml, 0.03 g in 10 ml), then a solution for infusion is prepared. The dose is set individually taking into account the initial concentration of calcium in the blood. For adults and elderly people with a calcium concentration in the blood below 3 mmol / l, the exchange dose is 0.015-0.03 g, with 3-3.5 mmol / l - 0.03-0.06 g, with a 3.5- 4 mmol / l - 0.09 g. The maximum exchange dose is 0.09 g. The total dose is given in the form of a single infusion (within 2 hours) or several infusions (within 2-4 days).
With Paget's disease, 0.03 g is administered as a 4-hour infusion for 3 days; A repetition of the course is possible.
When using the drug, moderate hypocalcemia, moderate hyperthermia, nausea, vomiting, bone pain, hematopoietic depression, allergic reactions, soreness at the site of administration are likely.
Contraindicated in severe violations of kidney function, pregnancy and lactation.
Incompatible with infusion solutions containing calcium.
Form release: lyophilized powder for injection solutions in bottles of 0.015; 0.03; 0.06 and 0.09 g (15, 30, 60 and 90 mg), complete with a solvent.
Storage: at a temperature not higher than +30 ° C.